|
1 Ballabh P, Braun A, Nedergaard M. The blood–brain barrier: An overview: Structure, regulation, and clinical implications. Neurobiol Dis, 2004, 16(1): 1–13.
|
|
2 Matter K, Balda MS. Signalling to and from tight junctions. Nat Rev Mol Cell Biol, 2003, 4(3): 225–236.
|
|
3 Ramsauer M, Krause D, Dermietzel R. Angiogenesis of the blood–brain barrier in vitro and the function of cerebral pericytes. FASEB J, 2002, 16(10)：1274–1276.
|
|
4 Lindahl P, Johansson BR, Levéen P, et al. Pericyte loss and microaneurysm formation in PDGF–B–deficient mice. Science, 1997, 277(5323): 242–245.
|
|
5 Abbott NJ. Astrocyte–endothelial interactions and blood–brain barrier permeability. J Anat, 2002, 200(6): 629–638.
|
|
6 Huber JD, Egleton RD, Davis TP. Molecular physiology and pathophysiology of tight junctions in the blood–brain barrier. Trends Neurosci, 2001, 24(12): 719–725.
|
|
7 De Boer AG, van der Sandt IC, Gaillard PJ. The role of drug transporters at the blood–brain barrier. Annu Rev Pharmacol Toxicol, 2003, 43: 629–656.
|
|
8 Scherrmann JM. Exchanges through the blood–brain barrier. Ann Pharm Fr, 2002, 60(6): 372–379.
|
|
9 Baranczyk–Kuzma A, Audus KL, Borchardt RT. Catecholamine–metabolizing enzymes of bovine brain microvessel endothelial cell monolayers. J Neurochem, 1986, 46(6): 1956–1960.
|
|
10 Korn A, Golan H, Melamed I, et al. Focal cortical dysfunction and blood–brain barrier disruption in patients with Postconcussion syndrome. J Clin Neurophysiol, 2005, 22(1): 1–9.
|
|
11 Fieschi C, Lenzi GL, Zanette E, et al. Effects on EEG of the osmotic opening of the blood–brain barrier in rats. Life Sci, 1980, 27(3): 239–243.
|
|
12 Marchi N, Angelov L, Masaryk T, et al. Seizure–promoting effect of blood–brain barrier disruption. Epilepsia, 2007, 48(4): 732–742.
|
|
13 Seiffert E, Dreier JP, Ivens S, et al. Lasting blood–brain barrier disruption induces epileptic focus in the rat somatosensory cortex. J Neurosci, 2004, 24(36): 7829–7836.
|
|
14 Engel J Jr, Kuhl DE, Phelps ME. Patterns of human local cerebral glucose metabolism during epileptic seizures. Science, 1982, 218(4567): 64–66.
|
|
15 Kann O, Kovács R, Njunting M, et al. Metabolic dysfunction during neuronal activation in the ex vivo hippocampus from chronic epileptic rats and humans. Brain, 2005, 128(Pt 10): 2396–2407.
|
|
16 De Vivo DC, Leary L, Wang D. Glucose transporter 1 deficiency syndrome and other glycolytic defects. J Child Neurol, 2002, 17(Suppl 3)：3S15–23.
|
|
17 Nordli DR Jr, De Vivo DC. The ketogenic diet revisited: Back to the future. Epilepsia, 1997, 38(7): 743–749.
|
|
18 Bough KJ, Gudi K, Han FT, et al. An anticonvulsant profile of the ketogenic diet in the rat. Epilepsy Res, 2002, 50(3): 313–325.
|
|
19 Rho JM, Robbins CA, Wenzel J, et al. An experimental ketogenic diet promotes long–term survival and reduces synaptic reorganization in the hippocampus of epileptic Kv1.1 null mutant mice. Epilepsia, 2005, 41(suppl 7): 34.
|
|
20 Marchi N, Hallene KL, Kight KM, et al. Significance of MDR1 and multiple drug resistance in refractory human epileptic brain. BMC Med, 2004, 2: 37.
|
|
21 Loscher W, Potschka H. Blood–brain barrier active efflux transporters: ATP–binding cassette gene family. NeuroRx, 2005, 2(1): 86–98.
|
|
22 Awasthi S, Hallene KL, Fazio V, et al. RLIP76, a non–ABC transporter, and drug resistance in epilepsy. BMC Neurosci, 2005, 27(6): 61.
|
|
23 Ellerkmann RK, Remy S, Chen J, et al. Molecular and functional changes in voltage dependent Na(＋) channels following pilocarpine–induced status epilepticus in rat dentate granule cells. Neuroscience, 2003, 119(2): 323–333.
|
|
24 Whitaker WR, Faull RL, Dragunow M, et al. Changes in the mRNAs encoding voltage–gated sodium channel types Ⅱ and Ⅲ in human epileptic hippocampus. Neuroscience, 2001, 106(2): 275–285.
|
|
25 Huguenard JR. Block of T–type calcium channels is an important action of succinimide antiabsence drugs. Epilepsy Curr, 2002, 2: 49–52.
|
|
26 Brooks–Kayal AR, Shumate MD, Jin H, et al. Selective changes in single cell GABA(A) receptor subunit expression and function in temporal lobe epilepsy. Nat Med, 1998, 4: 1166–1172.
|
|
27 Oby E, Caccia S, Vezzani A, et al. In vitro responsiveness of human–drug–resistant tissue to antiepileptic drugs: Insights into the mechanisms of pharmacoresistance. Brain Res, 2006, 1086(1): 201–213.
|